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Abstract
We report a case of a patient with tumor of the caecum with coexistent myasthenia
gravis (a form according to Osserman II A), requiring general anesthesia for
abdominal surgery. To reverse the neuromuscular block induced by vecuronium
was used sugammadex.
Key words: sugammadex, myasthenia gravis, neuromuscular monitoring,
vecuronium.
Introduction
Myasthenia gravis (MG) is a chronic autoimmune neuromuscular disease
manifesting with weakness and fatigue of skeletal muscles after physical
exercise, with a tendency to subside after periods of rest and typically
after taking anticholinesterase medication. Myasthenia gravis is
characterized by autoantibody attack of acetylcholine receptors at the
motor end plate of striated muscles, which results in variable muscle
weakness made worse by exercise [1]. Myasthenia gravis occurs in about
3-7 people per 100,000 – usually only sporadically.
The pathomechanism of the disease is associated with the formation
of autoimmune complexes in acetylcholine receptors on the postsynaptic
membrane of the neuromuscular junction. There is a close relationship
between immune processes accompanying myasthenia gravis and the
thymus, which has been found to contain production sites of B-cells
synthesizing anti-receptor antibodies [2]. 
Of major clinical importance is the classification of myasthenia gravis
developed by Osserman [3]. In 1958, Osserman proposed placing patients
with myasthenia gravis in five groups: I – localized (ocular), II – generalized
(mild or moderate), III – acute fulminating, IV – late severe, and V – muscle
atrophy. Later, Osserman divided group II into the subclassification: A (mild)
and B (moderate). Various modified criteria have been suggested over the
years. This classification allows one to grade the disease and assess the
perioperative risk and possible complications.
Myasthenic crisis may be defined as respiratory failure or delayed
postoperative extubation for more than 24 h resulting from myasthenic
weakness. Myasthenic crisis results from weakness of upper airway muscles
leading to obstruction and aspiration, weakness of respiratory muscles
leading to reduced tidal volumes, or from weakness of both muscle groups.
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Over the last four decades, the prognosis for
myasthenic crisis has dramatically improved from
a mortality rate of 75% to the current rate of less
than 5%. Common precipitating factors for
myasthenic crisis include respiratory infections,
aspiration, sepsis, surgical procedures, rapid tapering
of immune modulation, beginning treatment with
corticosteroids, exposure to drugs that may increase
myasthenic weakness, and pregnancy [4].
Surgery and anaesthesia in myasthenic gravis
patients are associated with an increased risk of
death and severe complications. The risk is mainly
related to a markedly higher sensitivity to muscle
relaxants observed in this group of patients, even
in periods of complete remission [5]. Myasthenia
patients often require prolonged ventilation in the
ICU setting [3, 6, 7]. A significant, though less
common, perioperative risk in myasthenic patients
is cholinergic crisis. 
The most proper approach during anaesthesia
in patients with myasthenia gravis is to apply deep
inhalational anaesthesia without muscle relaxing
agents. However, in abdominal and colorectal
surgery sometimes it is necessary to use muscle
relaxants in order to improve operating conditions
– to have better access to the operational field.
The safety of using muscle relaxing agents in
patients with myasthenia gravis undergoing major
surgical procedures has so far been assessed as
insufficient. Consequently, many anaesthesiologists
routinely decided against using muscle relaxants in
such clinical cases. The situation may change with
sugammadex, a novel agent recently introduced
into clinical practice. Sugammadex (ORG 25969) is
a modified γ-cyclodextrin [8-11] (su refers to sugar
and gammadex refers to the structural molecule 
γ-cyclodextrin). Unterbuchner et al. report the
successful use of the modified cyclodextrin
sugammadex in a myasthenic patient to reverse
a vecuronium-induced deep level of neuromuscular
block [12]. 
Case report
An 85-year-old white male patient was
scheduled for right-sided hemicolectomy due to
caecal tumour. At the time of admission to the
Department of General and Colorectal Surgery, the
patient had no complaints. 
The patient had been treated for myasthenia
gravis (Osserman stage IIa) since 2004. He had
a number of operations previously: appendectomy
(1940), left inguinal hernioplasty (1995), right
inguinal hernioplasty (2003) (reoperation in 2005
due to wound dehiscence). He received the
following medications: Mestinon (Pyridostigmini
bromidum) (3 × 1 tabl), Metazydyna (Trimetazidini
dihydrochloridum), Vicebrol (Vinpocetinum), Zoxon
(Doxazosini mesilas), Penestan (Finasteridum). The
patient was in the optimum condition for surgery,
with no absolute neurological contraindications to
the operation and no abnormalities identified in
laboratory tests.
The patient was scheduled for surgery under
general endotracheal anaesthesia (ASA class III).
The patient received no premedication due to
existing contraindications to benzodiazepines.
Induction of general anaesthesia was obtained
with propofol at 2 mg/kg. The patient was intu  -
bated with spontaneous respiration. Intubation
was uncomplicated. Immediately after the
intubation, remifentanil was given in a continuous
intravenous infusion of 50-150 μg/h. General
inhalation endotracheal anaesthesia was
performed according to procedures in place, using
sevoflurane in an air/oxygen mixture with low gas
flow. During anaesthesia, the patient’s mechanical
ventilation parameters were adjusted on the basis
of standard anaesthesiological evaluation. Doses
of anaesthetic agents were modified according to
the clinical assessment of the depth of ana  -
esthesia. Neuromuscular transmission was
blocked with vecuronium administered at
fractional doses of 1 mg until the required degree
of relaxation (with nerve stimulation monitoring
performed by the Datex-Ohmeda, mode TOF).
Maintenance doses of 1 mg (0.015 mg/kg body
weight) were administered every 50 min. Overall,
5 mg of vecuronium was administered during the
3-hour surgery. The management described above
resulted in excellent circulatory stabilization
(Table I).
Parameters Heart rate [beats/min] Non-invasive blood pressure [mmHg]
Induction 96 136/80 
Start of the operation 90 110/58
Every 15 min during 3 h  88; 86; 80; 75; 76; 78;  110/60; 112/59; 110/60; 100/58; 
of the operation 76; 72; 70; 70; 72 100/60; 100/60; 102/62; 100/62; 
110/58; 112/62; 112/60 
End of the operation 72 112/68
Extubation 72 120/80
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The patient underwent right-sided hemicolectomy
due to a caecal tumour with a diameter of approx.
8 mm infiltrating the mesentery. 
Emergence from anaesthesia was initiated at
the time of placement of the final skin suture.
Sugammadex (Bridion) in a 3 mg/kg bolus was
administered to reverse the neuromuscular block.
Neuromuscular block reversal was monitored by
the Datex-Ohmeda monitor simulation and clinical
signs. Five min after Bridion administration, the
patient regained efficient pulmonary respiration
and full logical contact was re-established. The
patient was extubated 6 min after Bridion admi  -
nistration.
Upon emergence from anaesthesia and
extubation, the patient was transferred to the
recovery room of the Anaesthesia and Intensive
Care Department. Full verbal contact and recovery
of consciousness with the patient was maintained
at the time of transfer to the recovery room. The
patient’s respiratory function and circulatory status
were uncompromised. Postoperative analgesia was
provided with remifentanil administered in
a continuous infusion. The patient stayed in the
recovery room of the Anaesthesia and Intensive
Care Department for 20 h before being transferred
to the Department of General and Colorectal
Surgery. During 6 days postoperative stay in the
Department of General and Colorectal Surgery, the
patient received 100 mg of Ketoprofenum
intravenously three times per day. The patient was
discharged on the 7th postoperative day.
Discussion
Myasthenia gravis patients, particularly those
undergoing major surgery and/or suffering from
concomitant disorders, require special individual
management in preparation for surgery [5],
appropriate selection and administration of
anaesthesia, and close monitoring postoperatively
[13]. This also applies to other groups of patients
with nervous system disorders including
myopathies and other muscular diseases [14, 15]. 
Sensitivity to non-depolarizing neuromuscular
blocking drugs is known to vary greatly between
myasthenic patients. Several studies using
a cumulative technique have shown the ED95 for
vecuronium to range from 6 μg/kg to 44 μg/kg.
Ocular myasthenic patients were less sensitive to
vecuronium than generalized myasthenic patients.
During general anaesthesia, neuromuscular
monitoring is essential to avoid problems of
prolonged neuromuscular block in myasthenic
patients. Vecuronium is a muscle relaxing agent
usually applied during the surgery in our hospital.
Epidural anaesthesia is less controllable in cases
of intraoperative haemorrhage. Epidural anaesthesia
causes sympathetic blockade with blood vessel
dilation and venous stasis; thus hypovolaemia as
a result of a haemorrhage is more difficult to
compensate than general endotracheal anaesthesia,
especially in elderly patients.
The best way of preparing a patient for a surgical
procedure is to recognize and understand both the
underlying medical condition and coexisting diseases.
Proper awareness of these makes it possible to
arrange individual pre-, peri- and postoperative
management. The procedure was followed in the
case reported here. Each stage of perioperative care
was thoroughly analysed and planned.
Currently used neuromuscular transmission
blockers are considered safe, with the recovery of
normal muscle function occurring after a period
specific to each drug. Acetylcholinesterase inhibitors
are used to accelerate the recovery of normal
neuromuscular transmission following admi  nistration
of non-depolarizing neuromuscular blockers. The time
of administration of these agents is of major
importance, since administered prematurely, they
can paradoxically result in neuromuscular block
reversal. As many as 60% of patients undergoing
surgery under general anaesthesia are believed to
be likely to experience problems with residual activity
of skeletal muscle relaxants (PORC – postoperative
residual curarization) [16-18]. The launch of
sugammadex, an agent reversing neuromuscular
block induced by steroid muscle relaxants, holds out
hope to steadily reduce the incidence of PORC [19].
Unquestionable benefits of the drug include: rapid
neuromuscular block reversal regardless of its depth
[20-22], documented drug safety and tolerance [23-
25], and – above all – an innovative mechanism of
action [25]. All the beneficial qualities of
sugammadex offer the possibility for using the drug
in patients who are expected to have problems with
proper ventilation and gas exchange.
In the case described here, sugammadex made
it possible to perform a safe general anaesthesia
procedure with skeletal muscle relaxants without
prolonging mechanical ventilation. The medical
literature contains isolated reports on the use of
sugammadex (with success) in patients with
myasthenia and other muscular dystrophies [12].
The authors of this report believe that sugam  -
madex as an agent used for muscle relaxation in
delivering anaesthesia to MG patients during
abdominal surgery could one day be recognized 
as the gold standard. Sugammadex, used in
combination with objective neuromuscular
monitoring, can be applied to reverse vecuronium-
induced neuromuscular blockade in patients with
myasthenia gravis.
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